Abstract
Aims To test whether the genetic variant CCR5Δ32 in the CC-chemokine receptor 5, which is known to lead to CCR5 deficiency, is associated with mortality in type 2 diabetes patients. Methods We examined the effect of presence or absence of the CCR5Δ32 on overall and cardiovascular mortality risk in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort, a type 2 diabetes patient cohort. Results We studied 756 patients with a mean duration of follow-up of 5.4 (± 1.4) years. 194 patients died during follow up of which 83 were cardiovascular deaths. 144 subjects (19%) carried the CCR5Δ32 deletion. CCR5Δ32 carriers had an adjusted hazard ratio of 0.62 (95%CI: 0.40–0.96; p = 0.03) for all-cause mortality and 0.63 (95%CI: 0.33–1.19; p = 0.16) for cardiovascular mortality. Conclusions The presence of CCR5Δ32 is associated with better survival in type 2 diabetes patients. These data suggest that it is worthwhile to explore the protective potential of pharmacological blockade of CCR5 in type 2 diabetic patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
